Results 21 to 30 of about 5,058,773 (393)

Prognostic nomograms for gastric carcinoma after D2 + total gastrectomy to assist decision-making for postoperative treatment: based on Lasso regression

open access: yesWorld Journal of Surgical Oncology, 2023
Objective This study aimed to establish novel nomograms that could be used to predict the prognosis of gastric carcinoma patients who underwent D2 + total gastrectomy on overall survival (OS) and progression-free survival (PFS).
Yifan Li, Min Bai, Yuye Gao
doaj   +1 more source

Prognostic Significance of Canine Mammary Tumor Histologic Subtypes: An Observational Cohort Study of 229 Cases [PDF]

open access: yes, 2017
Histopathology is considered the gold standard diagnostic method for canine mammary tumors. In 2011, a new histologic classification for canine mammary tumors was proposed.
Berlato, Davide   +3 more
core   +1 more source

TP53-inducible Glycolysis and Apoptosis Regulator (TIGAR) Metabolically Reprograms Carcinoma and Stromal Cells in Breast Cancer. [PDF]

open access: yes, 2016
A subgroup of breast cancers has several metabolic compartments. The mechanisms by which metabolic compartmentalization develop in tumors are poorly characterized. TP53 inducible glycolysis and apoptosis regulator (TIGAR) is a bisphosphatase that reduces
Bartrons, Ramon   +15 more
core   +2 more sources

Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. [PDF]

open access: yes, 2018
Fibrolamellar carcinoma has a distinctive morphology and immunophenotype, including cytokeratin 7 and CD68 co-expression. Despite the distinct findings, accurate diagnosis of fibrolamellar carcinoma continues to be a challenge.
Alves, Venancio Af   +27 more
core   +1 more source

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

open access: yesClinical Liver Disease, 2019
and Scope This guidance provides a data-supported approach to the diagnosis, staging, and treatment of patients diagnosed with hepatocellular carcinoma (HCC). A guidance document is different from a guideline.
J. Marrero   +7 more
semanticscholar   +1 more source

Alpha-fetoprotein–producing recurrent nasopharyngeal carcinoma: A case report

open access: yesSAGE Open Medical Case Reports, 2021
Alpha-fetoprotein hardly increased due to nasopharyngeal cancer. In this article, we reported a 57-year-old male nasopharyngeal carcinoma patient who had posttreatment subscapular metastasis with high serum alpha-fetoprotein but negative plasma Epstein ...
Zhen-Chong Yang   +7 more
doaj   +1 more source

Management of hepatocellular carcinoma: An update

open access: yesHepatology, 2011
Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated.
J. Bruix, M. Sherman
semanticscholar   +1 more source

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

open access: yesInternational Journal of Gynecological Cancer, 2020
A European consensus conference on endometrial carcinoma was held in 2014 to produce multi-disciplinary evidence-based guidelines on selected questions.
N. Concin   +27 more
semanticscholar   +1 more source

Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinoma

open access: yesCancer Communications, 2019
Background The National Comprehensive Cancer Network guidelines recommend intensity-modulated radiotherapy (IMRT) as the primary curative treatment for newly diagnosed nasopharyngeal carcinoma (NPC), but the radiation-related complications and relatively
You-Ping Liu   +19 more
doaj   +1 more source

Increased Angiogenin Expression Correlates With Radiation Resistance and Predicts Poor Survival for Patients With Nasopharyngeal Carcinoma

open access: yesFrontiers in Pharmacology, 2021
Background: Despite the development of such multiple therapeutic approaches, approximately 20% patients experience recurrence. Identification of molecular markers for stratifying the different risks of tumour recurrence and progression is considered ...
Shan-Shan Guo   +22 more
doaj   +1 more source

Home - About - Disclaimer - Privacy